Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2015-08-07

FDA Approved: IMODIUM MULTI-SYMPTOM RELIEF — Supplemental Application (Kenvue Brands LLC)

View source ↗

Summary

FDA approved a supplemental submission to add Imodium Multi-Symptom Relief (loperamide hydrochloride and dimethicone) to its product line under Kenvue Brands LL…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IMODIUM MULTI-SYMPTOM RELIEF (LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE)

Snippet

SUPPL AP for IMODIUM MULTI-SYMPTOM RELIEF (LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE)